Volume 12, Number 7—July 2006
Dispatch
Follow-up of 2003 Human West Nile Virus Infections, Denver, Colorado
Jennifer L. Patnaik*
, Heath Harmon†, and Richard L. Vogt*
, Heath Harmon†, and Richard L. Vogt*
Table 1
Prevalence of chronic health conditions and medication use among West Nile virus (WNV) study patients and multivariate model of predictors of more severe illness*
| Condition | All WNV patients (n = 656); prevalence, % | Meningitis patients (n = 84); adjusted OR (95% CI)† | Encephalitis patients (n = 41); adjusted OR (95% CI)† |
|---|---|---|---|
| High blood pressure | 12.2 | 1.0 (0.4–2.1) | 2.1 (1.0–4.6) |
| Diabetes | 6.1 | 0.8 (0.3–2.5) | 2.6 (1.0–6.5) |
| Heart disease | 3.8 | 1.4 (0.5–4.5) | 2.7 (0.9–8.2) |
| Cancer | 1.5 | 6.6 (1.6–27.5) | 7.5 (1.2–45.4) |
| Kidney disease | 1.2 | 2.3 (0.2–22.9) | 24.9 (4.7–132.5) |
| Steroids | 3.0 | 1.3 (0.4–4.6) | 1.8 (0.4–8.5) |
| Chemotherapy | 1.4 | 7.7 (1.5–40.0) | 25.9 (4.2–159.7) |
*CI, confidence interval; OR, odds ratio.
†Adjusted for sex and age >50 y.
Page created: December 16, 2011
Page updated: December 16, 2011
Page reviewed: December 16, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.